New EU indication for Novartis's Lucentis
This article was originally published in Scrip
Executive Summary
Novartis's Lucentis (ranibizumab) has now received EU approval for a fourth indication: choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).